MAP3K3
MOLECULAR TARGETmitogen-activated protein kinase kinase kinase 3
MAP3K3 (mitogen-activated protein kinase kinase kinase 3) is targeted by 32 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAP3K3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | erlotinib | 5.55 | 256 |
| 3 | alvocidib | 4.52 | 91 |
| 4 | foretinib | 4.34 | 76 |
| 5 | tozasertib | 4.33 | 75 |
| 6 | ruxolitinib | 4.23 | 68 |
| 7 | bosutinib | 4.08 | 58 |
| 8 | midostaurin | 3.85 | 46 |
| 9 | neratinib | 3.66 | 38 |
| 10 | nintedanib | 3.61 | 36 |
| 11 | canertinib | 3.53 | 33 |
| 12 | pelitinib | 3.50 | 32 |
| 13 | tae 684 | 3.43 | 30 |
| 14 | fedratinib | 3.40 | 29 |
| 15 | at 9283 | 3.09 | 21 |
| 16 | lestaurtinib | 3.04 | 20 |
| 17 | ruboxistaurin | 2.94 | 18 |
| 18 | r 406 | 2.83 | 16 |
| 19 | pha 665752 | 2.71 | 14 |
| 20 | kw 2449 | 2.64 | 13 |
| 21 | gsk 690693 | 2.64 | 13 |
| 22 | motesanib | 2.48 | 11 |
| 23 | su 014813 | 2.20 | 8 |
| 24 | amg 900 | 2.08 | 7 |
| 25 | pf 03814735 | 1.79 | 5 |
| 26 | Budesonide | 0.69 | 1 |
| 27 | Aripiprazole | 0.69 | 1 |
| 28 | Axitinib | 0.69 | 1 |
| 29 | Crizotinib | 0.69 | 1 |
| 30 | Desoximetasone | 0.69 | 1 |
| 31 | Guanabenz | 0.69 | 1 |
| 32 | 3',4'-didemethylnobiletin [Supplementary Concept] | 0.69 | 1 |
About MAP3K3 as a Drug Target
MAP3K3 (mitogen-activated protein kinase kinase kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 32 compounds with documented MAP3K3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAP3K3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.